Search

everythinglearnresearchcommunity

for

Search:↓

The user has been using finasteride and topical minoxidil for 15 months but is experiencing constant hair shedding, similar to telogen effluvium, despite stable widow peaks. They have checked for vitamin and mineral deficiencies, consulted specialists, and are considering further investigation like a scalp biopsy.

A 30-year-old with a family history of receding hairlines is considering starting finasteride due to gradual hairline recession. They are seeking advice on whether to begin treatment or if they are worrying unnecessarily.

PP405 shows potential for hair growth, with 31% of advanced balding men experiencing over 20% increase in hair density in 8 weeks. However, skepticism persists due to selective data presentation and lack of long-term results, with comparisons to treatments like minoxidil and finasteride.

Early hair loss causes emotional distress, and common coping strategies like fitness and fashion are inadequate. Treatments like finasteride, minoxidil, dutasteride, hair systems, and scalp micropigmentation were tried but were unsatisfactory.

Automatic-Law-3612's progress with hair loss treatments, including topical finasteride, topical dutasteride, minoxidil and pyrilutamide. They have been using these products for two weeks and noticed baby hairs in their temples getting longer.

A 28 year old using a hair loss prevention protocol to restore thinning hair, which includes finasteride, dutasteride, minoxidil, stemoxydine, alopecin, nizoral shampoo and microneedling; the user is now adding pyrilutamide solution to the regimen with the hope of improving their results. RU58841 was also ordered but not yet used.

The user is experiencing significant hair loss and has tried treatments like PRP therapy, topical and oral Minoxidil, Finasteride, and dietary changes, with limited success. They are concerned about losing more hair before a scheduled hair transplant and are advised to postpone the transplant to allow medications more time to work.

A clinical trial for Verteporfin as a hair loss treatment, and the potential for greater progress in treatments for hair loss in the future. Common treatments such as Minoxidil, Finasteride and RU58841 were discussed.

A young man regrets not starting finasteride treatment for hair loss sooner, noticing significant shedding just two months prior. He advises others experiencing early hair loss to act quickly and start treatment.

A 42-year-old had 2,100 grafts transplanted to the frontal third of the scalp, using treatments like Dutasteride, oral Minoxidil, ketoconazole shampoo, dermarolling, and PRP. They plan to add RU58841 and have scheduled SMP to improve cosmetic results.

Stem cell therapy shows promise in treating hair loss by mimicking DHT-resistant cells from the back of the head. Traditional treatments like finasteride are also discussed, but stem cells could potentially offer a more permanent solution.

miR-205, a tiny RNA, can stimulate hair growth by softening aging hair follicle stem cells in mice. Future tests aim to see if this can work in humans.

The conversation is about using Verteporfin with microneedling as a potential hair loss treatment that may regenerate hair follicles with minimal scarring. There are concerns about the optimal dosage and the DHT sensitivity of the new follicles.

The user is experiencing hair loss and has tried various treatments including topical and oral finasteride, minoxidil, dutasteride, and ketoconazole, but continues to lose hair. They are considering alternative solutions like hair systems due to the lack of improvement and a scalp condition called CVG.

Verteporfin treatment shows promise for hair regeneration and reducing scar tissue in hair transplants. Some users plan to try verteporfin with hair transplants, and it may also be combined with PRP in future experiments.

A 23-year-old male is experiencing diffuse hair loss and miniaturization, possibly due to high IGE levels after using tofacitinib. He seeks advice and has not yet consulted a dermatologist.

Hair loss discussion involves pyrilutamide treatment. Slow regrowth observed, expecting 10 baby hairs on temple regions after 1 year.

A 19-year-old is experiencing early hair loss, possibly due to oily skin, stress, poor diet, and lack of sleep. They have tried ketoconazole shampoo without success and plan to visit a dermatologist for further advice.

A South Korean company, Therazyne, has developed a promising hair loss treatment using a WNT chain surrogate that binds to Frizzled 7, with human follicle testing expected soon. Current treatments like minoxidil and finasteride are not seen as cures, and while optimism exists for future solutions like PP405, approval processes are lengthy.

A 22-year-old with high estradiol levels is considering starting finasteride for hair loss. They have an upcoming endocrinologist appointment to discuss whether they should proceed with the treatment.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.

A 19-year-old started treating male pattern baldness with topical minoxidil, finasteride tablets, microneedling, and is considering PRP injections. They are concerned about the effectiveness and timing of these treatments.

The conversation discusses severe hair loss, possibly due to telogen effluvium or male pattern baldness, lasting over three years. Suggested treatments include minoxidil, finasteride, and dermarolling, with a recommendation to consult a dermatologist.

PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Verteporfin considered for treating donor areas after hair transplants.

PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.

Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.

HairClone is offering a Dermal Papilla Cell Hair Multiplication procedure in Guatemala, raising questions about its effectiveness and regulatory reasons for the location. Users express skepticism and curiosity about the treatment's success and potential costs.

A user is concerned about receding hairlines and considers using finasteride and minoxidil but is hesitant due to potential side effects. Others advise starting treatment early to prevent further hair loss, emphasizing that finasteride is generally safe and effective for prevention.

Start finasteride and minoxidil early to prevent significant hair loss and maintain styling options. Finasteride can reduce acne and improve skin appearance.